Loading...
TTOO logo

T2 Biosystems, Inc.OTCPK:TTOO Aktierapport

Marknadsvärde US$84.1k
Aktiekurs
US$0.003
Mitt verkliga värde
Ej tillgänglig
1Y-98.0%
7D275.0%
Portföljens värde
​
Utsikt

T2 Biosystems, Inc.

OTCPK:TTOO Aktierapport

Börsvärde: US$84.1k

T2 Biosystems (TTOO) Aktievy

T2 Biosystems, Inc, ett in vitro-diagnostikbolag, utvecklar och säljer diagnostiska produkter och produktkandidater i USA och internationellt. Mer information

TTOO fundamental analys
Snöflinga Score
Värdering0/6
Framtida tillväxt0/6
Tidigare resultat0/6
Finansiell hälsa0/6
Utdelningar0/6

Riskanalys

Har inte ett meningsfullt börsvärde ( $84K )

Mycket volatil aktiekurs under de senaste 3 månaderna jämfört med US marknaden

De senaste finansiella rapporterna är mer än ett år gamla


TTOO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

T2 Biosystems, Inc. Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för T2 Biosystems
Historiska aktiekurser
Aktuell aktiekursUS$0.003
52 veckors högstaUS$0.17
52 veckors lägstaUS$0.0001
Beta0
1 månads förändring0%
3 månaders förändring650.00%
1 års förändring-98.00%
3 års förändring-99.90%
5 års förändring-99.90%
Förändring sedan börsintroduktionen-99.90%

Senaste nyheter och uppdateringar

Recent updates

Analysartikel • Apr 18

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

T2 Biosystems, Inc.'s ( NASDAQ:TTOO ) price-to-sales (or "P/S") ratio of 0.3x might make it look like a strong buy...
Seeking Alpha • Oct 13

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

T2 Biosystems (NASDAQ:TTOO) said on Thursday it had planned to to complete development of, and commercialize, a diagnostic test to detect early Lyme disease. The company expects to begin marketing and sales in the United States as a Laboratory Developed Test (LDT) in 2023. "We believe the T2Lyme Panel will potentially allow clinicians to ensure patients receive appropriate therapy faster, and prevent the negative impact of a delay in delivery of appropriate therapy and the overuse of antibiotics,” said John Sperzel, CEO of T2Biosystems. The molecular diagnostic test, T2Lyme panel, is designed to run on the FDA-cleared T2Dx Instrument and to detect Borrelia burgdorferi, the bacteria that causes Lyme disease. Lyme disease is a bacterial infection caused by the genes Borrelia and is transmitted to humans through the bite of infected ticks. About 476,000 Americans may get Lyme disease each year in the United States, according to the U.S. Centers for Disease Control and Prevention (CDC).
Seeking Alpha • Sep 29

T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M

Biomedical Advanced Research and Development Authority (or BARDA) is providing T2 Biosystems (NASDAQ:TTOO) an additional $3.7M in funding for the multiple-year cost-share contract. BARDA is a part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. The total potential BARDA funding if all contract options are exercised is $62M, reflecting a reduction in the scope of work under contract option 3. "We are pleased to advance the U.S. clinical trials for the T2Resistance Panel and T2Biothreat Panel, in collaboration with BARDA, and subsequently file submissions with FDA for U.S. regulatory clearance. These new products will expand the test menu on our T2Dx Instrument and have the potential to reduce the threat of antimicrobial resistance and protect the nation from biothreat pathogens.” stated John Sperzel, Chairman and CEO.
Seeking Alpha • Sep 22

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

T2 Biosystems (NASDAQ:TTOO) on Thursday said it had entered into a distribution agreement in the Baltic region for the sale of its products. Shares of the micro-cap diagnostics company jumped 17.3% to $0.10 after hours. It is worth noting that TTOO stock had earlier closed 11.8% lower to notch its eight straight session in the red. As per the agreement with the distributor, TTOO can sell products such as its T2Bacteria Panel, which can identify sepsis-causing bacteria, and its T2Candida Panel, which can detect fungal pathogens. "We are committed to expanding our commercialization worldwide and these new distribution agreements provide access to important markets in Lithuania, Latvia, and Estonia,” TTOO CEO John Sperzel said in a statement.
Seeking Alpha • Aug 26

T2 Biosystems' Survival Riddle

Summary T2's ongoing survival is a marvel to behold. T2's products fill key niches but have yet to show any viable commercial appeal. The elephant in the room for T2 shareholders is whether it will ever participate in any upside that may reside in its intellectual property. T2 Biosystems (TTOO) is a bygone favorite of mine that has bumped along on the fringes. I last discussed it in 08/2020's "COVID-19 Opportunity Knocks, T2 Answers". At the time, T2 was hoping to use interest in its rapid COVID diagnostics to place its T2Dx diagnostic device in hospitals. T2's strategy has been successful, but at an insufficient scale to turn it around. Placing devices is an important focus of T2's business development strategy. During T2's Q2 2022 earnings call (the "Call"), CEO Sperzel advised that its strategy was playing out as planned. It was gradually transitioning instruments that had been used for processing T2SARS-CoV-2 panels to use for sepsis testing. As a result, T2 has been experiencing an expected decline in COVID testing. [It] view[s] this development as a positive because it allows [it] to convert COVID-driven instruments to sepsis testing. As a reminder, [it] sold 47 T2Dx instruments to hospital microbiology labs during 2020, initially for COVID-19 testing, with the expectation that approximately 80% would convert to ... sepsis test panels over time. Selling instruments is an important driver of revenues for T2. Once an instrument is placed, it generates ongoing revenues. During the Call Sperzel explained: From an instrument pull-through perspective, in the United States, we achieved annualized sepsis tests utilization of $106,000 for legacy instruments. We continue to believe that annualized US sepsis test utilization will reach $200,000 per instrument and we have a number of customers that have already surpassed that target. We believe there is a significant market opportunity for our products, and we're excited to expand our presence in new and existing customers. During the Call, he also advised that T2's installed base of instruments includes a total of 155, 94 in the US and 61 internationally. When you consider that the instrument was FDA approved in 09/2014, this is a discouraging total. T2 has gone from troubled to extremely troubled, but somehow it keeps on ticking. My first (11/2019) T2 article, "T2: Navigating The Danger Zone", presented a cautiously optimistic view of this company. T2 had snagged its FDA approval back in 2014 for its instrument, but was, and still is, wallowing in the danger zone as it works to commercialize its T2Dx diagnostic device. It's hard to believe that T2, which currently (08/25/2022) trades for ~$0.13 went public in 08/2014 at ~$11.00 and subsequently traded >$20.00. Cheap does not a bargain make. T2's current down and nearly out share price reflects some very real problems that are dogging this company. Its rapid diagnostic products are quite attractive from any patient's point of view. The problem is that T2 has yet to figure out how to market them in commercially sufficient quantities to meet its expenses, much less earn a profit. T2's long-fought efforts for commercial viability have decimated the company's shares. It is struggling to maintain its NASDAQ listing. It currently anticipates a reverse stock split of somewhere between 1-for-10 and 1-for-50. If it would elect the 1 for 50 ratio, a shareholder who currently owns 50 shares trading at $0.13 would instead own 1 share worth $6.50; if it elects the 1 for 10 ratio, then shareholder would own 5 shares worth $1.30, still aggregating $6.50. T2 has an outstanding debt financing, originally for $40 million, with CRG. This financing has long been a concern of mine as I discuss at length in "T2: A Catch With A Catch". This concern is only exacerbated by T2's ongoing losses. The CRG loan is secured by a lien on substantially all of T2's assets, including its intellectual property. The loan requires T2 to maintain a minimum cash balance of $5 million along with other covenants. It is prepayable. In its latest 10-K, T2 advises: ...[It] intend[s] to continue to evaluate options to refinance the Term Loan Agreement, which becomes due on December 30, 2023. There can be no assurances that we will be able to refinance on terms favorable or at all. The amounts involved in any such transactions, individually or in the aggregate, may be material. Because the loan and its covenants are so important, T2 advised during the Call that it was then in compliance with all its loan covenants. As I recall from past review, this is a common bit of assurance that T2 has so far been able to provide during its quarterly earnings calls. T2 has a bevy of highly attractive products which have not proven financially viable. The issue with T2 that is especially frustrating relates to the extreme appeal of its products from a patient's point of view. Its current products are shown on its Q2 2022 presentation slide below: seekingalpha.com T2's rapid results are a godsend for patients who need to get a health screening, but who can ill afford long delays that are prevalent in the industry.

Aktieägarnas avkastning

TTOOUS BiotechsUS Marknad
7D275.0%-3.0%-0.3%
1Y-98.0%32.9%26.7%

Avkastning vs industri: TTOO presterade sämre än US Biotechs branschen som gav 32.9 % under det senaste året.

Avkastning vs Marknaden: TTOO presterade sämre än US marknaden som gav 26.7 % under det senaste året.

Prisvolatilitet

Is TTOO's price volatile compared to industry and market?
TTOO volatility
TTOO Average Weekly Movement621.0%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Stabil aktiekurs: TTOO s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: TTOO s veckovolatilitet har minskat från 671% till 621% under det senaste året, men är fortfarande högre än 75 % av US aktier.

Om företaget

GrundadAnställdaVD OCH KONCERNCHEFWebbplats
2006n/aCraig Jalbertinvestors.t2biosystems.com

T2 Biosystems, Inc. är ett in vitro-diagnostikföretag som utvecklar och säljer diagnostiska produkter och produktkandidater i USA och internationellt. Bolagets teknologi möjliggör detektion av patogener, biomarkörer och andra avvikelser i olika typer av orenade patientprover, inklusive helblod, plasma, serum, saliv, sputum, cerebral spinalvätska och urin. Bolaget erbjuder också T2Dx Instrument, ett bänkinstrument som kör olika diagnostiska tester från patientprover; T2Candida-panelen, en molekylärdiagnostisk testpanel direkt från blodet som upptäcker dödliga former av vanliga blodinfektioner, vilka orsakar sepsis och candidemi; T2Bacteria-panelen, en molekylärdiagnostisk testpanel direkt från blodet som upptäcker bakteriella patogener i blodinfektioner; T2Resistance-panelen, ett test direkt från blodet som identifierar karbapenemresistensgener; och T2Biothreat, en molekylärdiagnostisk testpanel direkt från blodet som körs på T2Dx Instrument och upptäcker patogener från biothreat.

T2 Biosystems, Inc. Sammanfattning av grunderna

Hur förhåller sig T2 Biosystems:s resultat och omsättning till dess börsvärde?
TTOO grundläggande statistik
BörsvärdeUS$84.14k
Vinst(TTM)-US$42.95m
Intäkter(TTM)US$7.68m
0.0x
P/S-förhållande
0.0x
P/E-förhållande

Är TTOO övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
TTOO resultaträkning (TTM)
IntäkterUS$7.68m
Kostnad för intäkterUS$26.70m
Bruttovinst-US$19.03m
Övriga kostnaderUS$23.93m
Intäkter-US$42.95m

Senast redovisade vinst

Sep 30, 2024

Nästa vinstdatum

n/a

Vinst per aktie (EPS)0
Bruttomarginal0.00%
Nettovinstmarginal0.00%
Skuld/egenkapitalförhållande0.0%

Hur har TTOO utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/21 05:41
Aktiekurs vid dagens slut2026/05/18 00:00
Intäkter2024/09/30
Årlig intjäning2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

T2 Biosystems, Inc. bevakas av 10 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Benjamin HaynorAlliance Global Partners
Paul KnightBrean Capital Historical (Janney Montgomery)
Karen KoskiBTIG